MetaVia is trading at $1.23, up +6.96% in after-hours trading, with no company-specific announcement or confirmed catalyst identified in the October 27 search.
- MetaVia’s latest located company announcement was October 13, when it appointed Sarah Browne chief medical officer.
- It noted anticipated fourth-quarter 2026 topline data from the DA-1726 Phase 1 trial, but predates this move and does not establish its cause.
- Shares rebounded after two consecutive declining closes; after-hours volume or activity details were unavailable.